Akira Iguchi1, Suguru Yamamoto2, Akira Oda3, Kenichi Tanaka3, Junichiro James Kazama3, Takako Saeki4, Hajime Yamazaki4, Ken Ishioka5, Tatsuo Suzutani5, Ichiei Narita6. 1. Department of Internal Medicine, Nagaoka Red-Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan. igucci4444@yahoo.co.jp. 2. Division of Blood Purification Therapy, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan. 3. Department of Nephrology and Hypertension, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan. 4. Department of Internal Medicine, Nagaoka Red-Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan. 5. Department of Microbiology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan. 6. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan.
Abstract
BACKGROUND: In patients with chronic kidney disease (CKD), dysbiosis in the gastrointestinal microbiome is thought to be associated with increased production of uremic toxins, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Sucroferric oxyhydroxide (SFO), an iron-based phosphate binder, may affect the gastrointestinal microbiome and the production of uremic toxins. We aimed to examine whether SFO administration affected distribution of gastrointestinal microbiome and serum uremic toxin levels in CKD patients undergoing hemodialysis. METHODS: In this single-center, open-label, interventional study, 18 maintenance hemodialysis patients with hyperphosphatemia were prescribed with SFO. We collected serum samples before and after 3 months of administration, and serum levels of IS and PCS were measured. A control group of 20 hemodialysis patients without SFO was evaluated. We evaluated gastrointestinal microbiome of patients pre- and post-SFO administration by 16S rDNA sequencing and bioinformatics analysis. RESULTS: Serum IS and PCS levels were significantly elevated after administration of SFO (IS before 2.52 ± 1.60 mg/dl vs. after 3.13 ± 1.51 mg/dl, P = 0.008; PCS before 2.32 ± 2.44 mg/dl vs. after 3.45 ± 2.11 mg/dl, P = 0.002), while serum IS and PCS levels did not change in the control group. Microbiome analysis in the SFO group showed no significant change in diversity and major components in phylum, class, order, family, gene, and species. CONCLUSION: Administration of SFO increased the serum levels of IS and PCS with no change of major components of gastrointestinal microbiome.
BACKGROUND: In patients with chronic kidney disease (CKD), dysbiosis in the gastrointestinal microbiome is thought to be associated with increased production of uremic toxins, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Sucroferric oxyhydroxide (SFO), an iron-based phosphate binder, may affect the gastrointestinal microbiome and the production of uremic toxins. We aimed to examine whether SFO administration affected distribution of gastrointestinal microbiome and serum uremic toxin levels in CKDpatients undergoing hemodialysis. METHODS: In this single-center, open-label, interventional study, 18 maintenance hemodialysis patients with hyperphosphatemia were prescribed with SFO. We collected serum samples before and after 3 months of administration, and serum levels of IS and PCS were measured. A control group of 20 hemodialysis patients without SFO was evaluated. We evaluated gastrointestinal microbiome of patients pre- and post-SFO administration by 16S rDNA sequencing and bioinformatics analysis. RESULTS: Serum IS and PCS levels were significantly elevated after administration of SFO (IS before 2.52 ± 1.60 mg/dl vs. after 3.13 ± 1.51 mg/dl, P = 0.008; PCS before 2.32 ± 2.44 mg/dl vs. after 3.45 ± 2.11 mg/dl, P = 0.002), while serum IS and PCS levels did not change in the control group. Microbiome analysis in the SFO group showed no significant change in diversity and major components in phylum, class, order, family, gene, and species. CONCLUSION: Administration of SFO increased the serum levels of IS and PCS with no change of major components of gastrointestinal microbiome.
Authors: Ranganathan Natarajan; Bohdan Pechenyak; Usha Vyas; Pari Ranganathan; Alan Weinberg; Peter Liang; Mary C Mallappallil; Allen J Norin; Eli A Friedman; Subodh J Saggi Journal: Biomed Res Int Date: 2014-07-24 Impact factor: 3.411
Authors: Mohamed M H Abdelbary; Christoph Kuppe; Sareh Said-Yekta Michael; Thilo Krüger; Jürgen Floege; Georg Conrads Journal: Sci Rep Date: 2022-06-10 Impact factor: 4.996
Authors: Solène M Laville; Ziad A Massy; Said Kamel; Jean Marc Chillon; Gabriel Choukroun; Sophie Liabeuf Journal: Toxins (Basel) Date: 2021-01-26 Impact factor: 4.546